✨ Free AI Report
Senti Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Senti Biosciences, Inc.
Company Research

Senti Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Senti Biosciences, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech with differentiated synthetic biology platform showing promising clinical data for AML but facing significant execution and capital risks. The FDA granted RMAT designation to SENTI-202, a potential first-in-class logic gated off-the-shelf CAR-NK investigational therapy for relapsed/refractory hematologic malignancies including AML, supporting clinical progress. However, the stock has.

What is Senti Biosciences, Inc.'s industry? Senti Biosciences, Inc. (sentibio.com) operates in Biotechnology - Cell and Gene Therapies. AskCyborg classifies Senti Biosciences, Inc. under Biotechnology - Cell and Gene Therapies in its company registry.

Senti Biosciences is a clinical stage biotechnology company developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candi...

4/ 10Mixed

Cyborg Score thesis

Early-stage biotech with differentiated synthetic biology platform showing promising clinical data for AML but facing significant...

Read the full analyst-debate transcript →
Industry Biotechnology - Cell and Gene Therapies
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Senti Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Senti Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Senti Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Senti Biosciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Senti Biosciences, Inc. Overview

Pro stress-test →

Senti Biosciences is a clinical stage biotechnology company developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.

Strategic Profile

Pro stress-test →

The company's platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases. Its core technologies include the SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.

Competitive Landscape

Pro stress-test →

Competitors in the cell therapy and synthetic biology space include companies such as Clearmind Medicine, Seres Therapeutics, FibroBiologics, and other emerging biotechs. Senti differentiates through its proprietary gene circuit platform that enables logic-gated control of therapeutic cells, providing potential advantages in safety and efficacy.

Industry Context

Senti Biosciences, Inc. operates in Biotechnology - Cell and Gene Therapies.

Key facts

Headquarters: South San Francisco, California · Market cap: $24.82M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Senti Biosciences, Inc..

  • Senti Bio completed enrollment in Phase 1 trial of SENTI-202 in February 2026
  • Data from 20 patients (18 with evaluable responses) in the ongoing multinational SENTI-202 trial showed high efficacy with 50% ORR and 42% CR/CRh
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Completed Phase 1 SENTI-202 trial enrollment
  • January 2026FDA granted RMAT designation to SENTI-202 for relapsed/refractory AML
  • +1 moreTrack every material event for Senti Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when Senti Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapiesCompeting off-the-shelf cell therapy platform→CAR-NK Cell TherapiesAlternative NK cell engineering approach→Cell Therapy PlatformsBroader cell therapy development focus→

Compare Senti Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Senti Biosciences, Inc. operates in Biotechnology - Cell and Gene Therapies. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Cell and Gene Therapies research →
NEW · MCP server

Ask your AI assistant about Senti Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Senti Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Senti Biosciences, Inc. do this quarter?”
“Is Senti Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Senti Biosciences, Inc. do?+
Senti Biosciences is a clinical stage biotechnology company developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candi...
What is Senti Biosciences, Inc.'s Cyborg Score?+
Senti Biosciences, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Senti Biosciences, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapies, CAR-NK Cell Therapies, Cell Therapy Platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Senti Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Senti Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Senti Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.